The treatment involves receiving the three medications before surgery. Tislelizumab is a newer type of drug that helps the immune system fight cancer cells, while carboplatin and paclitaxel are established chemotherapy medications that work by stopping cancer cells from growing and dividing. The medications will be given in cycles through an intravenous line, with specific doses calculated based on each patient’s body measurements.

The study will measure how well the treatment works by examining the cancer tissue removed during surgery and checking how many cancer cells remain after the treatment. Doctors will also monitor patients’ health during and after treatment to understand how safe this combination of medications is and how well it prevents the cancer from returning.

The trial will involve several medications, including fluorouracil, carboplatin, and cisplatin, which are types of chemotherapy drugs. These medications are given to help stop the growth of cancer cells. The purpose of the study is to see if the new treatment plan can improve the overall survival of patients with this type of cancer. Participants in the study will receive these treatments over a period of time, and their health will be monitored to see how well the treatment works.

The study will follow a specific course where participants will receive the treatments through intravenous infusion, which means the medication is given directly into a vein. The trial aims to find out if the new treatment plan can help patients live longer and control the cancer better than the current standard treatments. The study will also look at other factors, such as how the treatment affects the quality of life and any side effects that may occur. The ultimate goal is to find a more effective way to treat this type of cancer and improve the lives of those affected by it.

The purpose of the study is to determine how accurately the Gallium-68-Tilmanocept PET/CT can detect these lymph nodes compared to the traditional method using Technetium (99mTc). Participants in the study will undergo imaging with both methods before their surgery. This will help doctors understand which method is better at finding the lymph nodes that need to be examined for cancer spread.

During the study, participants will receive a small amount of the imaging substances near the tumor area. This is done to highlight the lymph nodes during the imaging process. The study aims to improve the way doctors detect and treat oral cancer by finding the most effective method for identifying affected lymph nodes. The trial will help gather important information that could lead to better outcomes for patients with this type of cancer.

The purpose of this research is to determine how effective and well-tolerated this combined treatment approach is for patients with advanced throat and larynx cancer. The treatment involves receiving both chemotherapy medications along with low-dose radiation therapy. During the study, patients will receive treatment over a period of up to 37 days.

The study will monitor how patients respond to the treatment by examining the cancer’s response, checking for any spread of the disease, and tracking overall patient survival. The research will also look at how low doses of radiation affect the body at both molecular and biochemical levels. Throughout the treatment period, doctors will carefully watch for and record any side effects that patients may experience.

The treatment involves taking Afatinib in the form of film-coated tablets, which are taken orally. The study will compare the effects of different doses of Afatinib to see how well it works in controlling the cancer and improving the quality of life for patients. Participants will be monitored for any side effects and how their cancer responds to the treatment over a period of time.

The purpose of this study is to gather information on the effectiveness of Afatinib in treating cancers associated with Fanconi anemia. The study will also look at how long the treatment effects last, the overall survival of patients, and any changes in their health-related quality of life. This information will help in understanding the potential benefits and risks of using Afatinib for this specific group of patients.

The purpose of this research is to determine if using both pembrolizumab and lenvatinib together works better than using pembrolizumab alone in preventing cancer from returning. Pembrolizumab is given through an intravenous infusion into a vein, while lenvatinib is taken as oral capsules. The treatment period may last up to 47 weeks.

The study will include patients whose cancer cells have a specific characteristic called PD-L1, which is a protein found on some cancer cells. Patients will receive regular medical check-ups throughout the study period to monitor their health and evaluate how well the treatment is working. The medications being studied are designed to help the body’s immune system fight cancer cells.